Crossmark

Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: 2 Turkish hospital experience

Crossref DOI link: https://doi.org/10.1016/j.acuroe.2019.06.004

Published Print: 2020-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Ekenel, M.

Karabulut, S.

Cil, I.

Zırtıloglu, A.

Aydın, E.

Tural, D.
License Information

Text and Data Mining valid from 2020-01-01
More Information

This article is maintained by: Elsevier

Article Title: Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: 2 Turkish hospital experience

Journal Title: Actas Urológicas Españolas (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.acuroe.2019.06.004

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.acuro.2019.06.007

Content Type: article

Copyright: © 2019 Published by Elsevier España, S.L.U. on behalf of AEU.